Plus Therapeutics and SpectronRx announced the signing of a Manufacturing Services Agreement (MSA) on November 6, 2024. This agreement is for the production of Rhenium (186 Re) Obisbemeda, an innovative radiotherapy for CNS cancers.
Under this strategic partnership, SpectronRx will utilize its facilities to produce late-stage clinical and commercial supplies of Rhenium (186 Re) Obisbemeda. SpectronRx operates over 170,000 sq ft of radiopharmaceutical contract development and manufacturing space.
This collaboration aims to enhance the supply chain redundancy for Plus Therapeutics. It positions the company to meet the demands of late-stage clinical trials and future commercial needs effectively.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.